 |
Florida Faculty and Professional Staff
Chris Liang
ASSOCIATE PROFESSOR ADJUNCT
Department of Molecular Therapeutics
TSRI - 2004
Joint Appointments Associate Professor, Chemistry
Education
Ph.D., Chemistry, Princeton University, 1989
Research Focus
Medicinal Chemistry and Drug Discovery
The current research focus in our lab is to discover novel protein kinase inhibitors as therapeutics for the treatment of human diseases such as cancer, arthritis, and asthma. We are planning to collaborate with scientists in advanced technology and biomedical research on other promising therapeutic targets.
Selected References
Huiping Guan, A. Douglas Laird, Robert A. Blake, Cho Tang, Chris Liang,
Design and Synthesis of Aminopropyl Tetrahydroindole Based Indolin-2-ones as Selective and Potent Inhibitors of Src and Yes Tyrosine Kinase, Bioorganic & Medicinal Chemistry Letters (2004), 14(1), 187-190.
X Wang, P Le, C Liang, J Chan, D Kiewlich, T Miller, D Harris, L Sun, A Rice, S Vasile, RA Blake, AR Howlett, N Patel, G McMahon, and KE Lipson Potent and Selective Inhibitors of the Met [Hepatocyte Growth Factor/Scatter Factor (HGF/SF) Receptor] Tyrosine Kinase Block HGF/SF-induced Tumor Cell Growth and Invasion. Mol. Cancer Ther. (2003); 2(11), 1085-92.
Li Sun, Chris Liang, Sheri Shirazian, Yong Zhou, Todd Miller, Jean Cui, Juri Y. Fukuda, Ji-Yu Chu, Asaad Nematalla, Xueyan Wang, Hui Chen, Anand Sistla, Tony C. Luu, Flora Tang, James Wei, and Cho Tang Discovery of 5-[5-Fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic Acid (2-Diethylaminoethyl)amide, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial and Platelet-Derived Growth Factor Receptor Tyrosine Kinase, J. Med. Chem. (2003), 46 (7), pp 1116 - 1119.
|
|
